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Abstract 
 
Despite internal complexity, tumor growth kinetics follow relatively simple laws that can be 
expressed as mathematical models. To explore this further, quantitative and discriminant 
analyses were performed for the purpose of comparing alternative models for their abilities to 
describe and predict tumor growth. The models were assessed against data from two in vivo 
experimental systems: an ectopic syngeneic tumor (Lewis lung carcinoma) and an 
orthotopically xenografted human breast carcinoma.  
 
The models included in the study comprised the exponential (with or without free initial 
volume), exponential-linear, power law, Gompertz, logistic, generalized logistic and von 
Bertalanffy models, as well as a model with dynamic carrying capacity. For the breast data, 
the observed linear dynamics were best captured by the Gompertz and exponential-linear 
models. The latter also exhibited the highest predictive power for this data set, with excellent 
prediction scores ( 80%) extending out as far as 12 days in the future. For the lung data, the 
Gompertz and power law models provided the most parsimonious and parametrically 
identifiable description. In contrast to the breast data, not one of the models was able to 
achieve a substantial prediction rate ( 70%) beyond the next day lung data point. In this 
context, adjunction of a priori information on the parameter distribution led to considerable 
improvement of predictions. For instance, forecast success rates went from 14.9% to 62.7% 
when using the power law model to predict the full future tumor growth curves, using just 
three data points. 
 
These results not only have important implications for biological theories of tumor growth and 
the use of mathematical modeling in preclinical anti-cancer drug investigations, but also may 
assist in defining how mathematical models could serve as potential prognostic tools in the 
clinic. 
 
Author Summary 
 
Tumor growth curves display relatively simple time curves that can be quantified using 
mathematical models. Herein we exploited two experimental animal systems to assess the 
descriptive and predictive power of nine classical tumor growth models. 
 
Several goodness-of-fit metrics and a dedicated error model were employed to rank the 
models for their relative descriptive power. We found that the model with the highest 
descriptive power was not necessarily the most predictive one. The breast growth curves had 
a linear profile that allowed good predictability. Conversely, not one of the models was able 
to accurately predict the lung growth curves when using only a few data points. To overcome 
this issue, we considered a method that uses the parameter population distribution, informed 
from a priori knowledge, to estimate the individual parameter vector of an independent 
growth curve. This method was found to considerably improve the prediction success rates. 
 
These findings may benefit preclinical cancer research by identifying models most 
descriptive of fundamental growth characteristics. Clinical perspective is also offered on what 
can be expected from mathematical modeling in terms of future growth prediction. 
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Introduction 
 
Neoplastic growth involves a large number of complex biological processes, including 
regulation of proliferation and control of the cell cycle, stromal recruitment, angiogenesis and 
escape from immune surveillance. In combination, these cooperate to produce a 
macroscopic expansion of the tumor volume, raising the prospect of a possible general law 
for the global dynamics of neoplasia. Quantitative and qualitative aspects of the temporal 
development of tumor growth can be studied in a variety of experimental settings, including 
in vitro proliferation assays, three-dimensional in vitro spheroids, in vivo syngeneic or 
xenograft implants (injected ectopically or orthotopically), transgenic mouse models or 
longitudinal studies of clinical images. Each scale has its own advantages and drawbacks, 
with increasing relevance tending to coincide with decreasing measurement precision. The 
data used in the current study are from two different in vivo systems. The first is a syngeneic 
Lewis lung carcinoma (LLC) mouse model, exploiting a well-established tumor model 
adopted by the National Cancer Institute in 1972 [1]. The second is an orthotopic human 
breast cancer xenografted in severe combined immunodeficient (SCID) mice [2]. 
 
Tumor growth kinetics has been an object of biological study for more than 60 years (see 
e.g. [3] as one of the premiere studies) and has been experimentally investigated extensively 
(see [4] for a thorough review and [5–8] for more recent work). One of the most common 
findings for animal [9] and human [10–12] tumors alike is that their relative growth rates 
decrease with time [13]; or equivalently, that their doubling times increase. 
 
These observations suggest that principles of tumor growth might result from general growth 
laws, often amenable to expression as ordinary differential equations [14]. The utility of these 
models can be twofold: 1) testing growth hypotheses or theories by assessing their 
descriptive power against experimental data and 2) estimating the prior or future course of 
tumor progression [9,15] either as a personalized prognostic tool in a clinical context [16–20], 
or in order to determine the efficacy of a therapy in preclinical drug development [21,22]. 
 
Cancer modeling offers a wide range of mathematical formalisms that can be classified 
according to their scale, approach (bottom-up versus top-down) or integration of spatial 
structure. At the cellular scale, agent-based models [23,24] are well-suited for studies of 
interacting cells and implications on population-scale development, but computational 
capabilities often limit such studies to small maximal volumes (on the order of the mm3). The 
tissue scale is better described by continuous partial differential equations like reaction-
diffusion models [19,25] or continuum-mechanics based models [26,27], when spatial 
characteristics of the tumor are of interest. When focusing on scalar data of longitudinal 
tumor volume (which is the case here), models based on ordinary differential equations are 
more adapted. A plethora of such models exist, starting from proliferation of a constant 
fraction of the tumor volume, an assumption that leads to exponential growth. This model is 
challenged by the aforementioned observations of non-constant tumor doubling time. 
Consequently, investigators considered more elaborate models; the most widely accepted of 
which is the Gompertz model. It has been used in numerous studies involving animal [9,28–
31] or human [12,15,30,32] data. Other models include logistic [30,33] or generalized logistic 
[11,31] formalisms. Inspired by quantitative theories of metabolism and its impact on 
biological growth, von Bertalanffy [34] derived a growth model based on balance equations of 
metabolic processes. These considerations were recently developed into a general law of 
biological growth [35] and brought to the field of tumor growth [36,37]. When the loss term is 
neglected, the von Bertalanffy model reduces to a power law (see [5,38] for applications of 
this model to tumor growth). An alternative, purely phenomenological approach led other 
investigators [39] to simply consider tumor growth as divided into two phases: an initial 
exponential phase then followed by a linear regimen. Recently, influences of the 
 4 
microenvironment have been incorporated into the modeling, an example being the inclusion 
of tumor neo-angiogenesis by way of a dynamic carrying capacity [40,41].  
 
Although several studies have been conducted using specific mathematical models for 
describing tumor growth kinetics, comprehensive work comparing broad ranges of 
mathematical models for their descriptive power against in vivo experimental data is lacking 
(with the notable exception of [30] and a few studies for in vitro tumor spheroids [33,42–44]). 
Moreover, predictive power is very rarely considered (see [42] for an exception, examining 
growth of tumor spheroids), despite its clear relevance to clinical utility. The aim of the 
present study is to provide a rational, quantitative and extensive study of the descriptive and 
predictive power of a broad class of mathematical models, based on an adapted 
quantification of the measurement error (uncertainty) in our data. As observed by others [45], 
specific data sets should be used rather than average curves, and this is the approach we 
adopted here. 
 
In the following sections, we first describe the experimental procedures that generated the 
data and define the mathematical models. Then we introduce our methodology to fit the 
models to the data and assess their descriptive and predictive powers. We conclude by 
presenting the results of our analysis, consisting of: 1) analysis of the measurement error 
and derivation of an appropriate error model, subsequently used in the parameters 
estimation procedure, 2) comparison of the descriptive power of the mathematical models 
against our two datasets, and 3) determination of the predictive abilities of the most 
descriptive models, with or without adjunction of a priori information in the estimation 
procedure. 
 
Materials and Methods 
 
Ethics statement 
 
Animal tumor model studies were performed in strict accordance with the recommendations 
in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. 
Protocols used were approved by the Institutional Animal Care and Use Committee (IACUC) 
at Tufts University School of Medicine for studies using murine Lewis lung carcinoma (LLC) 
cells (Protocol: #P11-324) and at Roswell Park Cancer Institute (RPCI) for studies using 
human LM2-4LUC+ breast carcinoma cells (Protocol: 1227M). Institutions are AAALAC 
accredited and every effort was made to minimize animal distress. 
 
Mice experiments 
 
Cell culture 
 
Murine Lewis lung carcinoma (LLC) cells, originally derived from a spontaneous tumor in a 
C57BL/6 mouse [46], were obtained from American Type Culture Collection (Manassas, VA). 
Human LM2-4LUC+ breast carcinoma cells are a metastatic variant originally derived from 
MDA-MD-231 cells and then transfected with firefly luciferase [47]. All cells were cultured in 
high glucose DMEM (obtained from Gibco Invitrogen Cell Culture, Carlsbad, CA or 
Mediatech, Manassas, VA) with 10%FBS (Gibco Invitrogen Cell Culture) and 5% CO2.  
 
Tumor Injections 
 
Subcutaneous mouse syngeneic lung tumor model 
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C57BL/6 male mice with an average lifespan of 878 days were used [48]. At time of injection 
mice were 6 to 8 weeks old (Jackson Laboratory, Bar Harbor, Maine). Subcutaneous 
injections of 106 LLC cells in 0.2 ml phosphate-buffered saline (PBS) were performed on the 
caudal half of the back in anesthetized mice.  
 
Orthotopic human xenograft breast tumor model 
LM2-4LUC+ cells (1 × 106 cells) were orthotopically implanted into the right inguinal mammary 
fat pads of 6- to 8-week-old female severe combined immunodeficient (SCID) mice obtained 
from the Laboratory Animal Resource at RPCI, as previously described [2]. 
 
Tumor measurements 
 
Tumor size was measured regularly with calipers to a maximum of 1.5 cm3 for the lung data 
set and 2 cm3 for the breast data set. Largest (L) and smallest (w) diameters were measured 
subcutaneously using calipers and the formula         was then used to compute the 
volume (ellipsoid). Volumes ranged 14 – 1492 mm3 over time spans from 4 to 22 days for the 
lung tumor model (two experiments of 10 animals each) and 202 – 1902 mm3 over time 
spans from 18 to 38 days for the breast tumor data (five experiments conducted utilizing a 
total of 34 animals). Plots of individual growth curves for both data sets are reported in Figure 
S1. 
 
Mathematical models 
 
For all the models, the descriptive variable is the total tumor volume, denoted by V, as a 
function of time t. It is assumed to be proportional to the total number of cells in the tumor. To 
reduce the number of degrees of freedom, all the models except the exponential    model 
had a fixed initial volume condition. Although the number of cells that actually remain in the 
established tumor is probably lower than the number of injected cells ( 60-80%), we 
considered   mm3 (     cells [49], i.e. the number of injected cells) as a reasonable 
approximation for       . 
 
Exponential-linear models 
 
The simplest theory of tumor growth presumes all cells proliferate with constant cell cycle 
duration TC. This leads to exponential growth, which is also valid in the extended cases 
where either a constant fraction of the volume is proliferating or the cell cycle length is a 
random variable with exponential distribution (assuming that the individual cell cycle length 
distributions are independent and identically distributed). As one modification, initial 
exponential phase can be assumed to be followed by a linear growth phase [39], giving the 
following Cauchy problem for the volume rate of change (growth rate): 
 
 {  
                                                    (1)  
 
Here, the coefficient    is the fraction of proliferative cells times        where    is either the 
constant cell cycle length or the mean cell cycle length (under the assumption of 
exponentially distributed cell cycle lengths). The coefficient    drives the linear phase. 
Assuming that the solution of the problem (1) is continuously differentiable uniquely 
determines the value of   as         ቀ       ቁ. The coefficient    denotes the initial volume. 
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From this formula, three models were considered: a) initial volume fixed to   mm3 and no 
linear phase        , referred to hereafter as exponential 1, b) free initial volume and no 
linear phase, referred to as exponential    and c) equation (1) with fixed initial volume of   
mm3, referred to as the exponential-linear model. 
 
Logistic and Gompertz models 
 
A general class of models used for quantification of tumor growth kinetics have a sigmoid 
shape, i.e. an increasing curve with one inflection point that asymptotically converges to a 
maximal volume, the carrying capacity, denoted here by  . This qualitatively reproduces the 
experimentally observed growth slowdown [9–12] and is consistent with general patterns of 
organ and organismal growth. The logistic model is defined by a linear decrease of the 
relative growth rate        in proportion to the volume: 
 
 {        (    )            (2)  
 
where   is a coefficient related to proliferation kinetics. This model can be interpreted as 
mutual competition between the cells (for nutrients or space, for instance), by noticing that 
under this model the instantaneous probability for a cell to proliferate is proportional to     . 
The logistic model has been used, for instance, in [30]. Others (such as [11]) have 
considered a generalization of the logistic equation, defined by 
 
 {       ቆ  (  ) ቇ            (3)  
 
that will be referred to as the generalized logistic model. Equation (3) has the explicit solution 
                               
 
which also provides an analytic solution to model (2) when    . When a different 
parameterization is employed, replacing   by     ), this model converges when     to the 
Gompertz model, defined by 
  
 {                        (4)  
 
Coefficient   here is the initial proliferation rate (at      mm3) and   is the rate of 
exponential decay of this proliferation rate. Although first introduced in [50] for a different 
purpose – the description of human mortality for actuarial applications – the Gompertz model 
became a widely-accepted representation of growth processes in general [51] and of tumor 
growth in particular. It was first successfully used in this regard [28] before its applicability 
was confirmed on large animal data sets [9,29] and for human breast data [32]. The essential 
characteristic of the Gompertz model is that it exhibits exponential decay of the relative 
growth rate. An analytic formula can be derived for the solution of (4): 
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           (      ) 
 
where we can see that asymptotically, the volume converges to a carrying capacity given 
by        . 
 
A unified model deriving these three sigmoidal models from specific biophysical assumptions 
about different types of cellular interactions can be found in [52]. 
 
Dynamic carrying capacity 
 
Taking the next step up in complexity brings us to a model that assumes a dynamic (time-
dependent) carrying capacity (CC) [40,41] that can be taken, for example, to represent the 
tumor vasculature. If one assumes that stimulation of the carrying capacity is proportional to 
the tumor surface, and neglects angiogenesis inhibition, this model can be formulated in 
terms of two coupled equations: 
 
 {  
            (  )                                (5)  
 
and will be referred to as the dynamic CC model. It should be noted that this model was first 
developed with the intent of modeling the effect of anti-angiogenic therapies on tumor growth 
and not strictly for describing or predicting the behavior of   alone. However, we integrated it 
into our analysis in order to investigate and quantify whether consideration of a dynamic 
carrying capacity could benefit these tasks. 
 
Von Bertalanffy and power law 
 
Von Bertalanffy [34], followed later on by others [35], proposed to derive general laws of 
organic growth from basic energetics principles. Stating that the net growth rate should result 
from the balance of synthesis and destruction, observing that metabolic rates very often 
follow the law of allometry (i.e. that they scale with a power of the total size) [34] and 
assuming that catabolic rates are in proportion to the total volume, he derived the following 
model for growth of biological processes 
 
 
            (6)  
 
Employing our usual assumption that            , we will refer to this model as the 
von Bertalanffy model (note that others [14,30] often identify this model as the specific case      , termed “second type growth”). It has already been successfully applied to describe 
tumor growth [36,37]. More elaborate considerations linking tumor growth, metabolic rate and 
vascularization leading to equation (6) can be found in [37]. That work also provides 
expressions of the coefficients in terms of measurable energetic quantities. Explicit solution 
of the model is given by 
      ቀ   ቀ        ቁ          ቁ      
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From the observation that our data does not exhibit a clear saturation phase, a qualitative 
feature of equation (6), we also considered another model, derived from (6), by neglecting 
the loss term, i.e. taking    . This model will be termed the power law model. Pushing 
further the reasoning of [34] and arguing that the rate of synthesis of new material, in the 
context of tumor growth, should be proportional to the number of proliferative cells (under the 
assumption of a constant cell cycle length), this model suggests that the proliferative tissue is 
proportional to   . This could be further interpreted as a possible fractional Hausdorff 
dimension of the proliferative tissue, when viewed as a metric subspace of the full tumor 
volume (viewed itself as a three-dimensional subset of the three-dimensional Euclidean 
space). This dimension would be equal to    and could be less than   when    . In this 
interpretation, the case      (i.e. dimension equal to  ) could correspond to a proliferative 
rim limited to the surface of the tumor. This implies that the tumor radius — proportional to      — grows linearly in time. Such linear growth of the tumor radius has been 
experimentally reported for tumor growth, for instance in the case of gliomas [18]. At the 
other extreme, a three-dimensional proliferative tissue (   ) represents proliferative cells 
uniformly distributed within the tumor and leads to exponential growth. Any power       
gives a tumor growth with decreasing growth fraction (and thus decreasing relative growth 
rate), for which the power law model provides a description in terms of a geometrical feature 
of the proliferative tissue. This model was first used for murine tumor growth description in 
[38] and was applied to human data in [5].  
 
Fit procedures and goodness of fit criteria 
 
Individual approach 
 
The main method we used to fit the models is based on individual fits for each animal. The 
underlying statistical framework is to consider the volume data     for animal   (     ) at 
time     (with         as realizations of a random variable     being generated by a 
(deterministic) model  (itself dependent on a parameter vector of length   (         )), as 
perturbed by random effects, assumed to be Gaussian. In mathematical terms: 
 
      (      )           (7)  
 
where the     are independent reduced centered Gaussian random variables and       is the 
standard deviation of the error. Statistical analysis of the measurement error was performed 
(see the Results section) and resulted in the following expression 
      {(   )                                           
 
For a given animal   and parameter set   , the likelihood       is defined as the probability 
of observing ቀ          ቁ under model , parameter set    and expression (7), i.e.  (  )  
 ቀ             ቁ. Considering that maximizing   is equivalent to minimizing     , it leads to 
a weighted least squares minimization problem with objective defined by 
 
   (  )  ∑(     (      )   )       (8)  
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Minimization was performed using the Matlab [53] function lsqcurvefit (trust-region 
algorithm), except for the generalized logistic model, for which the function fminsearch 
(Nelder-Mead algorithm) was employed (see supporting text S1 for more details on the 
numerical procedures). The resulting best-fit parameter vector was denoted  ̂ . Standard 
errors (  ) of the maximum likelihood estimator, from which confidence intervals can be 
derived, were used to quantify the reliability of the parameters estimated. These were 
computed from an a posteriori estimate of   , denoted       and the weighted jacobian 
matrix of the model for animal  , denoted      both defined by  
 
 
               ̂  ,      (          (     ̂  ))   (9)  
 
From these expressions, normalized standard errors can be approximated, in the context of 
nonlinear least squares regression, by [54] 
 
 
           ቀ     ቁ               (    )                 ̂      (10) 
 
Different initializations of the algorithm were systematically tested to establish the practical 
identifiability of the models (see supporting text S2).  
 
From the obtained  ̂ , we derived various indicators of the goodness of fit. The Akaike 
Information Criterion (AIC) [55,56] was used to compare models with different numbers of 
parameters by penalizing those that use greater numbers of parameters. It is defined, up to 
an additive constant that does not depend on the model, by  
 
           ቆ  ( ̂ )  ቇ      (11) 
 
where      . Due to the limited number of data for a given individual, we also 
considered a corrected version of the AIC, termed AICc [55,56]: 
 
                          (12) 
 
The Root Mean Squared Error (RMSE) is another classical goodness of fit criterion that also 
penalizes the lack of parameter parsimony in a model:  
 
       √          ̂   (13) 
 
Yet another criterion is the coefficient of determination: 
 
        ∑ ቀ     (     ̂ )ቁ      ∑ ቀ      ቁ       (14) 
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where    is the time average of the data points. This metric quantifies how much of the 
variability in the data is described by the model  and how much the model is better at 
describing the data than the mere mean value.  
 
Finally, we considered as an additional criterion of validity of a fit the p-value obtained from 
the Kolmogorov-Smirnov statistical test for normality of the weighted residuals, these being 
defined by  
 
 
                 ̂      (15) 
 
Population approach (mixed-effect models) 
 
The procedure we explained above considers all the animals within a group to be 
independent. On the other hand, the mixed-effect approach [57] consists of pooling all the 
animals together and estimating a global distribution of the model parameters in the 
population. More precisely, the individual parameter vectors           are assumed to be 
realizations of a random variable   (here taken to be log-normally distributed). The statistical 
representation is then formula (7) with   instead of   , together with 
             
 
Two coefficients (the vector   of length   and the     matrix  ) represent the total 
population, instead of the   parameter sets in the individual approach. Combined with an 
appropriate description of the error variance (derived from our error model), a population 
likelihood of all the data pooled together can be defined. Usually, no explicit formula can be 
computed for its expression, making its maximization a more difficult task. This is 
implemented in a software called Monolix [58], which maximizes the likelihood using the 
stochastic approximation expectation maximization (SAEM) algorithm [59]. Consistently with 
our results on the measurement error (see the Results section), the error model (i.e. the 
expression of   in (7)) was taken to be proportional to a fixed power        of the volume, 
although with a threshold volume      (because Monolix does not permit the setting of a 
threshold volume). From this estimation process, a population     , denoted        , was 
defined, using the same formula as (12) and the     returned by Monolix. 
 
Model prediction methods 
 
For a given animal   and model , the general setting considered for prediction was to 
estimate the model’s parameter set using only the first   data points and to use these to 
predict at a depth  , i.e. to predict the value at time      , provided that a measurement 
exists at this day (in which case it will be denoted by     ). The resulting bestfit parameter set 
was denoted   ̂  . 
 
Prediction metrics and success score 
 
Goodness of a prediction was quantified using the normalized error between a model 
prediction and the data point under consideration, defined by 
 
 
      |              ̂        | (16) 
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Prediction of a single time point was considered acceptable when the normalized error was 
lower than three, corresponding to a model prediction within three standard deviations of the 
measurement error of the data and generating success results in good agreement with direct 
visual examinations (see Figures S2 and S3). This allowed us to define a prediction score at 
the level of the population (denoted by    ), by the proportion of successful predictions 
among all animals having measurements both at times    and      (whose set will be 
denoted by      and total number by    T ). This metric is formally defined by  
 
      {             }    (17) 
 
We derived then a global score for each model by averaging over all possible values of   
and  . When the total number of animals over which the success score is computed is small, 
this could bias the success score (since for instance only one successfully predicted animal 
could give a success score of 100% if there is only one animal to predict). To lower this bias, 
we considered a minimal threshold for    , arbitrarily taken to 5 animals. The overall mean 
success is then defined by 
 
 
                           |             (18) 
 
When assessing prediction over the total future curve, thus involving several time points, we 
considered the median of the normalized errors: 
 
 
               (               ) (19) 
 
together with its associated prediction score        and population average        . 
 
The previous metrics being dependent on our underlying measurement error, we also 
considered the relative error and its population average, defined by 
 
 
      |              ̂       |                  ∑            (20) 
 
 
A priori information 
 
For each dataset and model, the total population was randomly and equally divided into two 
groups. Individual fits for the first group (the “learning” group) were performed using all the 
available data, generating mean values (  ̅̅ ̅     ̅̅ ̅) and standard deviations           of a 
parameter vector           within the population. This information was then used when 
estimating the individual parameter set of a given animal from the second group (the 
“forecast group”), based only on a subset of its data points, by penalizing the sum of squared 
residuals in the following way 
 
    (  )  ∑(     )      ∑(      ̅̅ ̅  )      (21) 
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with       defined by (15). This objective replaced the one defined in (8). The procedure was 
repeated 100 times (i.e. 100 random assignments of the total population between 10 
“learning” animals and 10 “forecast” animals). This number was sufficiently large to have 
reached convergence in the law of large numbers (no significant difference between 20 and 
100 replicates,       by Student’s t-test). Among these simulation replicates, we only 
considered as significant the cases where        For the lung tumor data set, this did not 
lead to any exclusion for most of the situations, the only exceptions being for      and      
where only 89/100 and 72/100 replicates were eligible, respectively. In contrast, for the 
breast tumor data and depths 1 to 10, respectively 99, 16, 76, 3, 100, 3, 100, 0, 34 and 77 
replicates were eligible. Therefore, results of     ,     ,     ,      and      were considered as 
non-significant and were not reported. 
 
Results 
 
Measurement error 
 
The following method was used for analysis of the error made when measuring tumor 
volume with calipers. One volume per time point per cage was measured twice within a few 
minutes interval. This gave a total of 133 measurements over a wide range of volumes (20.7 
– 1429 mm3). These were analyzed by considering the following statistical representation 
 
           
 
where   is a random variable whose realizations are the measured volumes,    is the true 
volume,   is a reduced centered Gaussian random variable, and    is the error standard 
deviation. The two measures, termed    and   , were, as expected, strongly correlated 
(Figure 1A,               ). Statistical analysis rejected variance independent of volume, 
i.e. constant   (       ,    test) and a proportional error model (   ) was found only 
weakly significant (       ,    test, see Figure 1B). We therefore introduced a dedicated 
error model, defined by 
 
   {                                          (22) 
 
Two main rationales guided this formulation. First, we argued that error should be larger 
when volume is larger, a fact that is corroborated by larger error bars for larger volumes on 
growth data reported in the literature (see Figure 4 in [2] for an example among many 
others). This was also supported by several publications using a proportional error model 
when fitting growth data (such as [42,60]). Since here such a description of the error was 
only weakly significant, we added a power to account for lower-than-proportional uncertainty 
in large measurements. Second, based on our own practical experience of measuring tumor 
volumes with calipers, for very small tumors, the measurement error should stop being a 
decreasing function of the volume because of detectability limits. This motivated the 
introduction of the threshold   . After exploration of several values of    and  , we found                 to be able to accurately describe dispersion of the error in our data 
(       ,    test, see Figure 1C). This yielded an empirical value of  ̂         
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We did not dispose of double measurements for the breast tumor data and the error analysis 
was performed using the lung tumor data set only. However, the same error model was 
applied to the breast tumor data, as both relied upon the same measurement technique. 
 
This result allowed quantification of the measurement error inherent to our data and was an 
important step in the assessment of each model’s descriptive power.  
 
Descriptive power 
 
We tested all the models for their descriptive power and quantified their respective goodness 
of fit, according to various criteria. Two distinct estimation procedures were employed. The 
first fitted each animal’s growth curve individually (minimization of weighted least squares, 
with weights defined from the error model of the previous section, see Material and 
Methods). The second method used a population approach and fitted all the growth curves 
together. Results are reported in Figure 2 and Tables 1 and 2. Parameter values resulting 
from the fits are reported in Tables 3 and 4. 
 
Figure 2.A depicts the representative fit of a given animal’s growth curve for each data set 
using the individual approach. From visual examination, the exponential 1 (1), logistic (2) and 
exponential-linear (1) models did not well explain lung tumor growth and the exponential 1 
(1) and logistic (2) models did not satisfactorily fit the breast tumor growth data. The other 
models seemed able to describe tumor growth in a reasonably accurate fashion.  
  
These results were further confirmed by global quantifications over the total population, such 
as by residuals analysis (Figure 2.C) and global metrics reported in Tables 1 and 2. When 
considering goodness-of-fit only, i.e. looking at the minimal least squared errors possibly 
reached by a model to fit the data (metric      in Tables 1 and 2), the generalized logistic 
model (3) exhibited the best results for both data sets (first column in Tables 1 and 2). This 
indicated a high structural flexibility that allowed this model to adapt to each growth curve 
and provided accurate fits. On the other hand, the exponential 1 (1) and logistic (2) models 
clearly exhibited poor fits to the data, a result confirmed by almost all the metrics (with the 
exception of the     ).  
 
Influence of the goodness-of-fit metric 
 
Being able to closely match the data is not the only relevant criterion to quantify the 
descriptive power of a model since parameter parsimony of the model should also be taken 
into account. Other metrics were employed that balanced pure goodness-of-fit and the 
number of parameters (see Materials and Methods for their definitions). Among them,      
exhibited the strongest penalization for a large number of parameters. However, this metric 
was in multiple instances in disagreement with the other metrics dealing with parsimony. For 
this reason, we also reported the values of    . These were found globally in accordance 
with the     . The         gave a weaker importance to the number of parameters, due to 
the large number of data points in the setting of the population approach, since all the 
animals were pooled together. For the same reason, values of         were almost identical 
to values of        and only the former were reported. Other structural and numerical 
differences (for instance, the individual approach used a deterministic optimizer while the 
population approach was based on a stochastic algorithm) also explained the discrepancies 
between the two approaches. When comparing the results generated by the two approaches, 
better individual fits were obtained using the individual approach (see Tables S2). Indeed, 
the population approach is better designed for settings where the number of data points is 
too low to individually estimate the parameters, which was not our case.  
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Taking all these considerations into account, we deemed the      metric to be a good 
compromise and used this criterion for ranking the models in Tables 1 and 2.  
 
Descriptive power and identifiability of the models for each data set 
 
Lung data 
Five models (generalized logistic (3), Gompertz (4), power law (6), dynamic CC (5) and von 
Bertalanffy (6)) were found to have similar      (Table 1), suggesting an identical 
descriptive power among them. However, having one less parameter, the Gompertz and 
power law models had smaller     (and much smaller     ) and should thus be preferred for 
parsimonious description of subcutaneous tumor growth of LLC cells. Having an additional 
degree of freedom translated into poor identifiability of the parameters for the generalized 
logistic (3), dynamic CC (5) and von Bertalanffy (6) models, as indicated by high standard 
errors on the parameter estimates (last column of Table 3) and low robustness of these 
estimates with regard to the initialization of the parameters (see the study of practical 
identifiability of the models in supplementary text S2 and Table S3). The Gompertz model (4) 
was also supported by the observation that the median value of   estimated by the 
generalized logistic model was close to zero. 
 
Breast data 
Superior fitting power was obtained by the exponential-linear model (1), for all but one of the 
metrics considered (  , see Table 2). For all the animals, the fits were in the linear phase of 
the model indicating linear tumor growth dynamics in the range of volumes observed. The 
Gompertz (4), generalized logistic (3) and power law (6) models still had high descriptive 
power, with mean      and     similar to the exponential-linear model (Table 2). Again, as 
a consequence of their larger number of parameters, the dynamic CC (5), von Bertalanffy (6) 
and generalized logistic (3) models exhibited very large standard errors of the parameter 
estimates as well as large inter-animal variability (Table 3). Consequently, moderate 
confidence should be attributed to the specific values of the parameters estimated by the fits, 
although this did not affect their descriptive power. 
 
As a general result for both data sets, all the models with two parameters were found to be  
identifiable (Tables 2 and 3). This was confirmed by a study of practical identifiability 
performed by systematically varying the initial condition of the minimization algorithm (see 
supporting text S2 and Table S3). For the theories that were able to fit (power law (6) and 
Gompertz (4) models for the lung tumor data and additionally the exponential-linear model 
(1) for the breast tumor data), the values of the parameters and their coefficient of variability 
provided a fairly good characterization of the tumor growth curves dynamics and inter-animal 
variability. In particular, the power   of the power law model identified in the lung tumor data 
set seemed to accurately represent the growth of the LLC experimental model (low standard 
errors and coefficient of variation). Results of inter-animal variability suggested a larger 
heterogeneity of growth curves in the breast tumor data than in the lung tumor data set, 
which could be explained by the different growth locations (orthotopic versus ectopic). 
 
Taken together, our results show that, despite the complexity of internal cell populations and 
tissue organization, at the macroscopic scale tumor growth exhibits relatively simple 
dynamics that can be captured through mathematical models. Models with three parameters, 
and more specifically the generalized logistic model (3), were found highly descriptive but not 
identifiable. For description of subcutaneous in vivo tumor growth of LLC cells, the Gompertz 
(4) and power law (6) models were found to exhibit the best compromise between number of 
parameters and descriptive power. Orthotopic growth of LM2-4LUC+ cells showed a clear 
linear trend in the range of observed volumes, well captured by the exponential-linear (1), 
power law (6) and Gompertz (4) models. 
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Forecasting tumor growth. Individual curves 
 
The two models that were shown unable to describe our data in the previous section, namely 
the exponential 1 (1) and logistic (3) models, were excluded from further analysis. The 
remaining ones were assessed for their predictive power. The challenge considered was to 
predict future growth based on parameter estimation performed on a subset of the data 
containing only   data points (with      for a given  ). We refer to the Materials and 
Methods section for the definitions of prediction metrics and success scores. 
 
Models’ predictive power for     
 
The initial scenario considered the prediction of future growth based on the first five data 
points. 
 
Lung data 
Figure 3 presents a representative example of predictions in this setting for a given animal of 
the lung tumor data set (mouse 2, see Figure S2.A for specific predictions for each of the 
animals using the Gompertz model (4)). The success criterion that we defined in the 
Materials and Methods was found to be in agreement with direct visual examination. 
According to this metric, the power law (6), dynamic CC (5) and von Bertalanffy (6) models 
seemed able to accurately predict the global future growth curve while the exponential    (1), 
exponential-linear (1), Gompertz (4) and generalized logistic (3) models, although passing 
close to the next data point, were less accurate for prediction of the remainder of the data. 
 
Quantifications of the goodness of the prediction on the total population, reported in Table 5 
(see the metric       ) showed that the prediction success depended on the mouse under 
consideration. Despite the low predictive power of the curve of Figure 3, the Gompertz model 
(together with the von Bertalanffy model), had the best global score       , predicting 9/20 
mice. A more detailed examination of mice for when the Gompertz model (4) failed (Figure 
S2.A), indicated that most of time the model interpreted too strongly an initial slowdown. This 
resulted in large underestimation of future data points (see mice 3, 4, 5 and 13 in Figure 
S2.A). The same predictive pattern and almost identical predictive curves were observed for 
the von Bertalanffy (6), dynamic CC (5) and power law (6) models. On the other hand, when 
using the generalized logistic model (3), some growth curves showed a different predictive 
pattern (see Figure S2.B). Due to the high flexibility already observed in the descriptive 
study, this model often saturated early to fit the first five data points, resulting in poor future 
predictions. 
 
Study of short term predictability, for instance at a depth of two days (score     , Table 5), 
showed that no more than an average relative precision of 19% should be expected, for all 
predictions taken together.  
 
Breast data 
Substantial differences and overall better predictability were found for the same setting 
(   ) for the breast tumor data. For instance, the average relative precision at a depth of 
two days was 13%, using the exponential-linear model. This improved predictability was also 
expressed by a higher       , although caution should be employed in this comparison since 
the number of points predicted in        was lower in the breast tumor setting than in the 
lung tumor setting (see Figures S2.A and S3). Predictions of all animals using the 
exponential-linear model were reported in Figure S3 and showed that the linear dynamics 
exhibited by the breast tumor growth curves could explain this better predictability.  
 
Variable number of data points used for prediction and prediction depth 
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For evaluation of the global predictive properties of the models, we investigated varying the 
number   of data points used for estimation of the parameters (respectively       and       for the lung and breast data sets) and the prediction depth   (respectively       and       ). Results are reported in Figure 4 and Tables 5 and 6.  
 
In contrast with its high descriptive power (Tables 1 and 2), the generalized logistic model (3) 
was found to have the lowest overall mean success rate with all       settings pooled 
together for both data sets (Tables 5 and 6). In this case, high descriptive power and low 
predictive ability were linked together. Indeed, the generalized logistic model (3) suffered 
from its flexibility when put in a predictive perspective. As expressed before for the case    , the model fitted very well the initial parts of the curves, but this resulted in premature 
saturation of the tumor growth and eventually low prediction scores (see Figure S2.B). On 
the other hand, high success scores were obtained when the model was fed with a lot of data 
(  large, see Figure 4.A). This result emphasizes that a model’s high descriptive abilities 
might not always translate into high predictive power. 
 
Lung data 
According to their predictive patterns in the       plane, the four models von Bertalanffy (6), 
Gompertz (4), dynamic CC (5) and power law (6) could be grouped together, and only one of 
them is presented in Figure 4.A (the von Bertalanffy model (6), see Figure S4.A for the 
predictive patterns of the other models). Interestingly, what occurred with the generalized 
logistic model (lower predictive power associated to high flexibility) was not observed for the 
two other three-parameter models (von Bertalanffy (6) and dynamic CC (5)). This indicates a 
rigidity of these models similar to the power law (6) and Gompertz (4) models, despite an 
additional degree of freedom. Taken together, these four models had moderate predictive 
power, with mean overall prediction scores lower than 45%. The exponential    (1) and 
exponential-linear (1) models were found to have even lower predictive power (Table 5), 
suggesting that the exponential initial phase of the growth in this data set, might not be 
predictive of future growth. In most of the situations, the prediction success was found to 
increase with   and decrease with   (see the von Bertalanffy model (6) in Figure 4.A). 
Whenever this did not occur (such as in the exponential    (1) predictive pattern of Figure 
4.A) it was, for most of the cases, due to the fact that the two sets of animals predicted in the 
two situations were different. In other words, if          was observed with     , the 
animals in     were usually different from the ones in      (see Materials and Methods, 
Models prediction methods for the definition of      and see also Figure S2). This did not 
imply that the same data points were less accurately predicted with   larger. Surprisingly, 
this last case was nevertheless observed in some rare settings. For instance, with mouse 19, 
the generalized logistic model successfully predicted the volumes at days 17 and 18 using 
four data points (corresponding to             and      ), but failed to do so with five data 
points (corresponding to             and      ), see Figure S4.  
 
Breast data 
For the breast tumor data, predictability was found to be higher than in the lung tumor data, 
with an excellent overall mean prediction success of the exponential-linear model (1) (83.8%, 
see Table 6). Consequently, this model ranked 20 percentage points higher than the second 
best model (dynamic CC (5)). The average score of the exponential-linear model (1) resulted 
from a wide spread predictability in the       plane (Figure 4.B), with high success rates 
even at the far future prediction depth with a small number of data points (for instance, all 
five of the animals having a data point at       were successfully predicted,          %). 
While the exponential    (1) showed low predictive power, the von Bertalanffy (6), Gompertz (4), power law (6) and dynamic CC (5) models were similarly predictive, having relatively 
good overall mean success rates (ranging from 58.8% to 63.3%, see Table 6).  
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As a general result, based on the distribution of relative prediction errors (Figure 4, bottom) 
all the models had a general trend for underestimation of predictions. 
 
Tumor growth was more predictable in late phases 
 
Different tumor growth regimens exist within the same growth curve and, in a clinically 
relevant setting, diagnosis might occur when the tumor is already large. To explore this 
further, we tested the predictability of the next day data point (or the second next day when 
using the breast tumor data, because in this case measurements were performed every two 
days) in two opposite situations: either using the three first available data points (scores      
and      and relative errors       and      ) or using the first three of the last four 
measurements, as quantified by similar metrics denoted            ,         and       . Volume 
ranges predicted were 303   128 mm3 and 909   273 mm3 in the early phase for the lung 
tumor and breast tumor data respectively, versus 1245   254 mm3 and 1383   211 mm3 in 
the late phases. In this last setting, in order not to artificially inject the information of the first 
volume being 1 mm3 at day 0, we modified the von Bertalanffy, dynamic CC, generalized 
logistic, Gompertz, and power law models by fixing their initial times and volumes to the 
previous measurement (the fifth from the end). Interestingly, the results obtained were 
substantially different between the two growth phases. Better predictions were obtained 
when predicting the end of the curve, reaching excellent scores of 12-15/16 animals 
successfully predicted in the case of the LLC data (and average relative errors smaller or 
equal than 15%, see Table 5). Similar improvements were observed for the breast tumor 
data, with a 63% increase from      to       for the power law model and up to an 87% 
increase for the exponential    (see the bracketed numbers in Tables 5 and 6). Hence, the 
late phase of tumor growth appeared more predictable, possibly because of smaller 
curvatures of the growth curves that led to better identifiability of the models when using a 
limited number of data points for estimation of the parameters.  
 
Overall, our results showed equivalent predictive power of the von Bertalanffy (6), dynamic 
CC (5), power law (6), and Gompertz (4) models for prediction of future tumor growth curves 
of subcutaneous LLC cells, with substantial prediction rates ( 70%) requiring at least four 
data points and at a depth no larger than one day. The exponential-linear model was better 
suited for the orthotopic xenograft breast tumor data, with success rates larger than 70% in 
most of the       cases, including excellent scores at greater depths. 
 
Forecasting tumor growth. A priori information. 
 
When relatively fewer data points were used, for example with only three, individual 
predictions based on individual fits were shown to be globally limited for the lung tumor data, 
especially over a large time frame (Figure 4.A, Table 5). However, this situation is likely to be 
clinically relevant since few clinical examinations are performed before the beginning of 
therapy. On the other hand, large databases might be available from previous examinations 
of other patients and this information could be useful to predict future tumor growth in a 
particular patient. In a preclinical setting of drug investigation, tumor growth curves of 
animals from a control group could be available and usable when inferring information on the 
individual time course of one particular treated animal. 
 
An interesting statistical method that could potentiate this a priori information consists in 
learning the population distribution of the model parameters from a given database and to 
combine it with the individual parameter estimation from the available restricted data points 
on a given animal. We investigated this method in order to determine if it could improve the 
predictive performances of the models. Each dataset was randomly divided into two groups. 
One was used to learn the parameter distribution (based on the full time curves), while the 
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other was dedicated to predictions (limited number of data points). For a given animal of this 
last group, no information from his growth curve was used to estimate the a priori 
distributions. The full procedure was replicated 100 times to ensure statistical significance, 
resulting in respectively 2000 and 3400 fits performed for each model. We refer to the 
Materials and Methods for more technical details. Results are reported in Figure 5. 
 
Lung data 
Predictions obtained using this technique were significantly improved, going from an average 
success score of 14.9%   8.35% to 62.7%   11.9% (means   standard deviations) for 
prediction of the total future curve with the power law model (6) (see Figure 5.A). This model 
allowed predictions to be made at large future depths. For instance, predictions 7 days in the 
future could reasonably be considered (average success rate of 50.6%, power law model (6), 
see Figure 5.C), while their success rate was very low with direct individual prediction 
(6.07%). Prediction successes reached 90% (power law model (6)) at the closer horizon of 
the next day data point (    ), while success rate was only 57.1% using an individual 
approach (Figure 5.B). Other small horizon depths also reached excellent prediction scores 
(Figure 5.C). The largest improvement of success rates for the power law model was 
observed for      that went from an average score of 6.86% (with standard deviation 7.47) to 
an average score of 75.2% (with standard deviation 12.9), representing more than an 11-fold 
increase. We report in Figure S5 the details of predictions with and without a priori 
information for all the animals within a given forecast group from the lung tumor data set 
(power law model (6)). It can be appreciated how additional information on the parameter 
distribution in the estimation procedure significantly improved global prediction of the tumor 
growth curves. The impact of the addition of the a priori information was however less 
important when using more data points for the estimation (results not shown). 
 
Breast data 
Due to its already high prediction score without adjunction of a priori information, the 
exponential-linear model did not benefit from the method. For the next day data point of the 
breast tumor growth curves, predictability was already almost maximal without adjunction of 
a priori information and thus no important impact was observed. 
 
For both data sets, not all the models equally benefited from the addition of a priori 
information (Figure 5). Models having the lowest parameter inter-animal variability, such as 
the power law (6), Gompertz (4), exponential-linear (1), and exponential    (1) models (Table 
3), which also had better practical identifiability (Tables 2 and S3), exhibited great benefit. In 
contrast, the models with three parameters showed only modest benefit or even decrease of 
their success rates (see        and      for the von Bertalanffy model (6) on the breast tumor 
data in Figure 5.B), with the exception of the generalized logistic model (3) on the breast 
tumor data. In these cases, adjunction of a priori information translated into poor 
enhancement of predictive power because the mean population parameters did not properly 
capture the average behavior within the population and were therefore not very informative. 
On the other hand, models such as the power law model (6) on the lung tumor data set, 
whose coefficient   characterized particularly well the growth pattern (Table 3), had a more 
informative a priori distribution that translated into the highest improvement of predictive 
power. For the generalized logistic model (3) on the breast data, the mean parameters were 
able to inform the linear regimen of the growth phase and thus protected the model from too 
early saturation. 
 
These results demonstrated that addition of a priori information in the fit procedure 
considerably improved the forecast performances of the models, in particular when using a 
small number of data points and low-parameterized models for data with low predictability, 
such as the power law model for the lung tumor data set. 
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Discussion 
 
Error model 
 
In our analysis, constant variance of the error was clearly rejected and although a 
proportional error (used by others [33]) was not strictly rejected by statistical analysis 
(      ), a more adequate error model to our data was developed. However, using a 
proportional or even constant error model did not significantly affect conclusions as to the 
descriptive power of the models, identifying the same models (Tables 1, 2) as most adequate 
for description of tumor growth (results not shown). Nevertheless, the use of an appropriate 
error model could have important implications in the quantitative assessment of a model’s 
descriptive performance and rejection of inaccurate tumor growth theories. Interestingly, 
using the same human tumor growth data, Bajzer et al. [60] found the assumption of 
proportional error variance to favor the Gompertz model for descriptive ability, whereas 
Vaidya and Alexandro [30] had observed the logistic model to be favored, under a constant-
variance assumption. The error model used might additionally have important implications on 
predictions. Although detailed analysis of the impact of the error model on prediction power is 
beyond the scope of the present study, we performed a prospective study of predictive 
properties when using a constant error model on the lung tumor data and found changes in 
the ranking of the models (results not shown). 
 
Theories of growth 
 
As expected, our results confirmed previous observations [9–11,13,29,32] that tumor growth 
is not continuously exponential (constant doubling time) in the range of the tumor volumes 
studied, ruling out the prospect of a constant proliferating fraction. A less expected finding 
was that the logistic model (linear decay in volume of the relative growth rate) was also 
unable to describe our data, although similar results have been observed in other 
experimental systems [31,33]. On the other hand, the Gompertz and power law models could 
give an accurate and identifiable description of the growth slowdown, for both data sets. 
More elaborate models such as the generalized logistic, von Bertalanffy, and dynamic CC 
models could describe them as well. However, their parameters were found not to be 
identifiable from only tumor growth curves, in the ranges of the observed volumes. Additional 
data could improve identifiability, such as relating to later growth and saturation details. It 
should be noted in this case that the dynamic CC model was not designed with the intent to 
quantify tumor growth, but rather to describe the effects of anti-angiogenic agents on global 
tumor dynamics. Because the model carries angiogenic parameters that are not directly 
measureable, or even inferable, from the experimental systems we used, it stands to reason 
that they would not be easily identifiable from the data. Kinetics under the influence of 
antiangiogenic therapy might thus provide useful additional information that could render this 
model identifiable. For the breast tumor experimental system, the slowdown was 
characterized by linear dynamics and was most accurately fitted by the exponential-linear 
model. Observed was exponential growth from the number of injected cells (during the 
unobserved phase) that switched smoothly to a linear phase (exponential-linear model). It 
should be noted that in the breast tumor data set, no data were available during the initiation 
phase (below 200 mm3) and only the linear part of a putative exponential-linear growth was 
observed. Explorations of the kinetics of growth during the initial phase (at volumes below 
the mm3) are needed for further clarification. 
 
Despite structural similarities, important differences were noted in the parameter estimates 
between the two experimental models, in agreement with other studies emphasizing 
differences between ectopic and orthotopic growth [61,62]. Our results and methodology may 
 20 
help to identify the impact on kinetics of the site of implantation, although explicit 
comparisons could not be made here due to the differences in the cell lines used. 
 
The Gompertz model (exponential decay in time of the relative growth rate) was able to fit 
both data sets accurately, consistent with the literature [13,15,29,31,33]. One of the main 
criticisms of the Gompertz model is that the relative tumor growth rate becomes arbitrarily 
large (or equivalently, the tumor doubling time gets arbitrarily small) for small tumor volumes. 
Without invoking a threshold this becomes biologically unrealistic. This consideration led 
investigators [13,63] to introduce the Gomp-exp model that consists in an initial exponential 
phase followed by Gompertzian growth when the associated doubling time becomes realistic. 
This approach could also be applied to any decreasing relative growth rate model. We did 
not consider it in our analysis due to the already large initial volume and the lack of data on 
the initiation phase where the issue is most relevant. 
 
The power law model was also able to describe the experimental data and appeared as a 
simple, robust, descriptive and predictive mathematical model for murine tumor growth 
kinetics. It suggests a general law of macroscopic in vivo tumor growth (in the range of the 
volumes observed): only a subset of the tumor cells proliferate and this subset is 
characterized by a constant, possibly fractional, Hausdorff dimension. In our results, this 
dimension (equal to   ) was found to be significantly different from two or three (       by 
Student’s t-test) in 14/20 mice for the lung tumor data set and 13/34 mice for the breast 
tumor data, suggesting effectively a fractional dimension. A possible explanation of this 
feature could come from the fractal nature of the tumor vasculature [64,65], an argument 
supported by others who have investigated the link between tumor dynamics and vascular 
architecture [37]. More precisely, the branching nature of the vascularization generates a 
fractal organization [37,64,65] that could in turn produce a contact surface of fractional 
Hausdorff dimension. Considering further that the fraction of proliferative cells is proportional 
to this contact surface (for instance because proliferative cells are limited to an area at fixed 
distance from a blood vessel or capillary, due to diffusion limitations), this could make the 
connection between fractality of the vasculature and proliferative tissue. These 
considerations could therefore provide a mechanistic explanation for the growth rate decay 
that naturally happens when the dimension of the proliferative tissue is lower than three. Our 
results were obtained using two particular experimental systems: an ectopic mouse 
syngeneic lung tumor and an orthotopic human xenograft breast tumor model. Although 
consistent with other studies that found the power law model adequate for growth of a murine 
mammary cell line [38] or for description of human mammography density distribution data 
[5], these remain to be confirmed by human data. This model should also be taken with 
caution when dealing with very small volumes (at the scale of several cells for instance) for 
which the relative growth rate becomes very large. Indeed, the interpretation of a fractional 
dimension then fails, since the tumor tissue can no longer be considered a continuous 
medium. In this instance, it may be more appropriate to consider exponential growth in this 
phase [37]. 
 
Prediction 
 
Our results showed that a highly descriptive model (associated to large flexibility) such as the 
generalized logistic model, might not be useful for predictions, while well-adapted rigidity – as 
provided by the exponential-linear model on the breast tumor data – could lead to very good 
predictive power. Interestingly, our study revealed that models having low identifiability (von 
Bertalanffy and dynamic CC) could nevertheless exhibit good predictive power. Indeed, over 
a limited time span, different parameter sets for a given model could generate the same 
growth curves, which would be equally predictive.  
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For the Gompertz model, predictive power might be improved by using possible correlations 
between the two parameters of this model, as reported by others [15,63,66–68] and 
suggested by our own parameter estimates (       for both data sets, results not shown). 
 
If a backward prediction is desired (for instance for the identification of the inception time of 
the tumor), the use of exponential growth might be more adapted for the initial, latency 
phase, e.g. by employment of the Gomp-exp model [13,63].  
 
Clinical and preclinical implications 
 
Translating our results to the clinical setting raises the possibility of forecasting solid tumor 
growth using simple macroscopic models. Use of a priori information could then be a 
powerful method and one might think of the population distribution of parameters being 
learned from existing databases of previous patient examinations. However, the very strong 
improvement of prediction success rates that we obtained partly comes from the important 
homogeneity of our growth data (in particular the LLC data) that generated a narrow and very 
informative distribution of some parameters (for instance parameter   of the power law 
model), which in turn powerfully assisted the fitting procedure. In more practical situations 
such as with patient data, more heterogeneity of the growth data should be expected that 
could alter the benefit of the method. For instance, in some situations, growth could stop for 
arbitrarily long periods of time. These dormancy phases challenge the universal applicability 
of a generic growth law such as the Gompertz or power law [69]. Description of such 
dormancy phenomena could be integrated using stochastic models that would elaborate on 
the deterministic models reviewed here, as was done by others [70] to describe breast 
cancer growth data using the Gompertz model. Moreover, further information than just tumor 
volume could be extracted from (functional) imaging devices, feeding more complex 
mathematical models that could help design more accurate in silico prediction tools [18,71].  
 
Our analysis also has implications for the use of mathematical models as valuable tools for 
helping preclinical anti-cancer research. Such models might be used, for instance, to 
specifically ascertain drug efficacy in a given animal, by estimating how importantly the 
treated tumor deviates from its natural course, based on a priori information learned from a 
control group. Another application can be for rational design of dose and scheduling of anti-
cancerous drugs [22,72,73]. Although integration to therapy remains to be added (and 
validated) to models such as the power law, more classical models (exponential-linear [39] or 
dynamic CC [41]) have begun to predict cytotoxic or anti-angiogenic effects of drugs on 
tumor growth. Our methods have allowed precise quantification of their respective descriptive 
and predictive powers, which, in combination with the models’ intrinsic biological foundations, 
could be of value when deciding among such models which best captures the observed 
growth behaviors in relevant preclinical settings. 
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Table 1: Fit performances of the tumor growth models for the lung data
Model 1
I
χ2 AIC AICc AICcpop RMSE R
2 p > 0.05 #
Generalized logistic 0.12 (0.019 - 0.42) [1] -13 (-30 - 0.98) [3] 0.7 [6] 2114 [6] 0.4 (0.17 - 0.82) [1] 0.98 (0.94 - 1) 100 3
Gompertz 0.155 (0.019 - 0.67) [4] -13.4 (-32 - 2.4) [1] -7.62 [1] 2108 [5] 0.41 (0.16 - 0.93) [2] 0.97 (0.82 - 1) 100 2
Power law 0.155 (0.016 - 0.71) [5] -13.4 (-34 - 2.9) [2] -7.59 [2] 2091 [2] 0.41 (0.15 - 0.96) [3] 0.96 (0.78 - 1) 100 2
Dynamic CC 0.136 (0.013 - 0.61) [2] -12.5 (-32 - 3.5) [4] 1.19 [7] 2063 [1] 0.42 (0.14 - 0.96) [4] 0.97 (0.82 - 1) 100 3
Von Bertalanffy 0.14 (0.016 - 0.67) [3] -12.5 (-32 - 4.4) [5] 1.19 [8] 2096 [3] 0.42 (0.16 - 1) [5] 0.97 (0.81 - 1) 100 3
Exponential V0 0.217 (0.0069 - 0.91) [6] -10.7 (-34 - 5.1) [6] -4.85 [3] 2099 [4] 0.49 (0.096 - 1.1) [6] 0.93 (0.68 - 1) 100 2
Exponential-linear 0.22 (0.048 - 0.76) [7] -8.51 (-17 - 3.8) [7] -2.7 [4] 2174 [7] 0.51 (0.27 - 1) [7] 0.96 (0.91 - 0.99) 100 2
Logistic 0.232 (0.05 - 0.73) [8] -8.34 (-18 - 3.4) [8] -2.52 [5] 2214 [8] 0.52 (0.27 - 0.98) [8] 0.96 (0.92 - 0.99) 100 2
Exponential 1 1.36 (0.31 - 2.4) [9] 6.01 (-5.4 - 13) [9] 8.31 [9] 2442 [9] 1.2 (0.59 - 1.6) [9] 0.64 (0.28 - 0.94) 15 1
Models were ranked in ascending order of the RMSE, defined by expression (13). For each metric, indicated are the mean value
(among all animals) and in parenthesis the minimal and maximal values (not reported for AICc as they were redundant with the
range of AIC). When reported, value inside brackets is the rank of the model for the underlying metric. The model ranking first is
highlighted in bold. For animal j, 1
Ij
χ2(βˆj) is the minimal value of the objective that was minimized in the individual fits approach
(see (8)), divided by the number of time points Ij , and represents the variance of the weighted residuals. AIC and AICc are defined
in (11) and (12), AICcpop is the AICc resulting from the mixed-effect estimation (see Materials and Methods) and R
2 is defined in
(14). Values reported in the p column are percentages of animals were Kolmogorov-Smirnov test for normality of residuals was not
rejected at the significance level of 0.05. # = number of parameters. J = 20 animals.
2
Table 2: Fit performances of the tumor growth models for the breast data (J = 34 animals)
Model 1
I
χ2 AIC AICc AICcpop RMSE R
2 p > 0.05 #
Exponential-linear 0.0919 (0.016 - 0.49) [2] -11.7 (-25 - 1) [1] 0.798 [1] 2832 [1] 0.34 (0.16 - 0.83) [1] 0.92 (0.66 - 0.99) 100 2
Gompertz 0.0976 (0.015 - 0.33) [4] -11.3 (-28 - -0.85) [2] 1.21 [2] 2866 [3] 0.35 (0.14 - 0.68) [2] 0.92 (0.67 - 0.99) 100 2
Generalized logistic 0.0814 (0.0037 - 0.33) [1] -10.7 (-26 - 0.19) [4] 11.9 [6] 2870 [5] 0.36 (0.096 - 0.76) [3] 0.94 (0.8 - 0.99) 100 3
Power law 0.102 (0.016 - 0.32) [5] -10.9 (-22 - -0.017) [3] 1.53 [3] 2913 [7] 0.36 (0.16 - 0.71) [4] 0.92 (0.61 - 0.99) 100 2
Exponential V0 0.118 (0.011 - 0.37) [7] -9.86 (-20 - 1) [5] 2.61 [4] 2870 [4] 0.39 (0.13 - 0.78) [5] 0.9 (0.56 - 0.99) 100 2
Von Bertalanffy 0.0928 (0.015 - 0.32) [3] -9.77 (-26 - 1.2) [6] 11.9 [7] 2876 [6] 0.39 (0.15 - 0.8) [6] 0.93 (0.67 - 0.99) 100 3
Dynamic CC 0.11 (0.018 - 0.5) [6] -8.58 (-20 - 3.2) [7] 13 [9] 2862 [2] 0.42 (0.21 - 0.94) [7] 0.91 (0.58 - 0.99) 100 3
Logistic 0.145 (0.0037 - 0.42) [8] -8.1 (-22 - -0.13) [8] 4.37 [5] 2921 [8] 0.43 (0.078 - 0.76) [8] 0.86 (0.65 - 0.99) 100 2
Exponential 1 2.19 (0.62 - 3.4) [9] 8.77 (0.62 - 13) [9] 12.6 [8] 3518 [9] 1.6 (0.85 - 2) [9] -0.91 (-5.9 - 0.88) 53 1
Table 3: Parameter values estimated from the fits. Lung data
Model Par. Unit Median value (CV) Mean
normalized std
error (CV)
Power law
a
î
mm3(1−γ) · day−1
ó
0.921 (38.9) 11.9 (48.7)
γ - 0.788 (9.41) 4 (53.4)
Gompertz
a
⇥
day−1
⇤
0.742 (25.3) 6.02 (51.3)
β
⇥
day−1
⇤
0.0792 (42.4) 13.7 (65.4)
Exponential-linear
a0
⇥
day−1
⇤
0.49 (19.3) 3.08 (41.5)
a1
⇥
mm3 · day−1
⇤
115.6 (22.6) 15.7 (40.7)
Dynamic CC
a
⇥
day−1
⇤
0.399 (106) 447 (89.8)
b
⇥
mm−2 · day−1
⇤
2.66 (241) 395 (176)
K0
⇥
mm3
⇤
2.6 (322) 6.5e+04 (345)
Von Bertalanffy
a
î
mm3(1−γ) · day−1
ó
7.72 (112) 1.43e+04 (155)
γ - 0.947 (13.5) 40.9 (73)
b
⇥
day−1
⇤
6.75 (118) 2.98e+07 (222)
Generalized logistic
a
⇥
day−1
⇤
2555 (148) 2.36e+05 (137)
K
⇥
mm3
⇤
4378 (307) 165 (220)
α - 0.0001413 (199) 2.36e+05 (137)
Exponential V0
V0
⇥
mm3
⇤
13.2 (47.9) 28.9 (55)
a
⇥
day−1
⇤
0.257 (15.4) 7.49 (48.3)
Logistic
a
⇥
day−1
⇤
0.502 (17.5) 3.03 (48.9)
K
⇥
mm3
⇤
1297 (23.1) 17.2 (43.8)
Exponential 1 a
⇥
day−1
⇤
0.399 (13.8) 2.87 (24.5)
Shown are the median values within the population and in parenthesis the coefficient
of variation (CV, expressed in percent and defined as the standard deviation within
the population divided by mean and multiplied by 100) that quantifies inter-animal
variability. Last column represents the normalized standard errors (nse) of the maximum
likelihood estimator, defined in (11).
Table 4: Parameter values estimated from the fits. Breast data
Model Par. Unit Median value (CV) Mean
normalized std
error (CV)
Power law
a
î
mm3(1−γ) · day−1
ó
1.32 (74.1) 31.2 (48.6)
γ - 0.58 (23) 12.1 (62.2)
Gompertz
a
⇥
day−1
⇤
0.56 (18.4) 7.52 (43)
β
⇥
day−1
⇤
0.0719 (26.4) 12.5 (65.5)
Exponential-linear
a0
⇥
day−1
⇤
0.31 (16.8) 6.22 (65.9)
a1
⇥
mm3 · day−1
⇤
67.8 (33.2) 12.9 (45.4)
Dynamic CC
a
⇥
day−1
⇤
2.63 (81.3) 597 (339)
b
⇥
mm−2 · day−1
⇤
0.829 (399) 1.33e+03 (571)
K0
⇥
mm3
⇤
12.7 (525) 6.48e+03 (361)
Von Bertalanffy
a
î
mm3(1−γ) · day−1
ó
2.32 (113) 1.17e+04 (181)
γ - 0.918 (22.5) 128 (65.5)
b
⇥
day−1
⇤
0.808 (132) 1.48e+08 (300)
Generalized logistic
a
⇥
day−1
⇤
2753 (131) 7.41e+05 (160)
K
⇥
mm3
⇤
1964 (557) 232 (433)
α - 2.675e-05 (166) 7.41e+05 (160)
Exponential V0
V0
⇥
mm3
⇤
68.2 (57.2) 34.5 (50.8)
a
⇥
day−1
⇤
0.0846 (27.7) 13.7 (44.1)
Logistic
a
⇥
day−1
⇤
0.305 (10.2) 3.17 (34.9)
K
⇥
mm3
⇤
1221 (31.4) 11.8 (73.8)
Exponential 1 a
⇥
day−1
⇤
0.223 (5.9) 3.72 (21.3)
Shown are the median values within the population and in parenthesis the coefficient
of variation (CV, expressed in percent and defined as the standard deviation within
the population divided by mean and multiplied by 100) that quantifies inter-animal
variability. Last column represents the normalized standard errors (nse) of the maximum
likelihood estimator, defined in (11).
Table 5: Predictive power. Lung data
Model Overall mean
success
S5,glob S5,2 RE5,2 S3,1 RE3,1 S
f
3,1 RE
f
3,1
Von Bertalanffy 44.5 9/20 7/11 0.19 (0.016 - 0.51) 7/14 0.29 (0.011 - 1.08) 15/16 [87.5] 0.10 (0.007 - 0.26)
Dynamic CC 42.0 7/20 7/11 0.20 (0.010 - 0.48) 7/14 0.27 (0.002 - 1.01) 13/16 [62.5] 0.14 (0.012 - 0.65)
Power law 42.0 7/20 6/11 0.21 (0.019 - 0.52) 8/14 0.29 (0.011 - 1.08) 15/16 [64.1] 0.08 (0.007 - 0.29)
Gompertz 41.5 9/20 7/11 0.25 (0.069 - 0.57) 6/14 0.30 (0.030 - 1.08) 15/16 [119] 0.10 (0.001 - 0.30)
Exponential V0 39.3 6/20 6/11 0.33 (0.039 - 1.48) 9/14 0.31 (0.035 - 1.20) 15/16 [45.8] 0.09 (0.000 - 0.27)
Exponential linear 36.0 8/20 5/11 0.22 (0.037 - 0.43) 10/14 0.21 (0.029 - 0.99) 15/16 [31.2] 0.10 (0.010 - 0.33)
Generalized logistic 33.9 5/20 5/11 0.28 (0.069 - 0.57) 5/14 0.31 (0.030 - 1.08) 12/16 [110] 0.14 (0.006 - 0.30)
Models are presented in descending order of overall mean success (defined in (18)). Sn,d, defined in (17), is the success score for
prediction when using n data points and predicting at future depth d, i.e. time tn+d (see Materials and Methods). For relative errors
(20), mean value among animals is reported with ranges in parenthesis. Sf3,1 and RE
f
3,1 stand for the success rates and relative errors
for predictions of the late phase (see text for details). Reported in brackets in the Sf3,1 column are the percent increase between S3,1
and Sf3,1.
Table 6: Predictive power. Breast data
Model Overall mean
success
S5,glob S5,2 RE5,2 S3,2 RE3,2 S
f
3,2 RE
f
3,2
Exponential linear 83.8 20/25 17/23 0.13 (0.014 - 0.36) 4/7 0.27 (0.079 - 0.84) 17/20 [49] 0.10 (0.001 - 0.32)
Dynamic CC 63.3 20/25 19/23 0.14 (0.013 - 0.53) 4/7 0.28 (0.071 - 0.87) 13/20 [14] 0.18 (0.001 - 0.43)
Power law 62.3 18/25 17/23 0.15 (0.028 - 0.57) 3/7 0.33 (0.092 - 0.97) 14/20 [63] 0.14 (0.001 - 0.41)
Gompertz 59.0 18/25 17/23 0.15 (0.001 - 0.54) 3/7 0.33 (0.076 - 0.97) 13/20 [52] 0.17 (0.001 - 0.61)
Von Bertalanffy 58.8 18/25 17/23 0.15 (0.008 - 0.54) 3/7 0.31 (0.077 - 0.87) 14/20 [63] 0.14 (0.007 - 0.43)
Exponential V0 47.7 14/25 17/23 0.16 (0.003 - 0.66) 3/7 0.37 (0.065 - 1.24) 16/20 [87] 0.13 (0.024 - 0.37)
Generalized logistic 34.2 13/25 15/23 0.18 (0.001 - 0.54) 3/7 0.27 (0.100 - 0.73) 14/20 [63] 0.15 (0.001 - 0.41)
Models are presented in descending order of overall mean success (defined in (18)). Sn,d, defined in (17), is the success score for
prediction when using n data points and predicting at future depth d, i.e. time tn+d (see Materials and Methods). For relative errors
(20), mean value among animals is reported with ranges in parenthesis. Sf3,2 and RE
f
3,2 stand for the success rates and relative errors
for predictions of the late phase (see text for details). Reported in brackets in the Sf3,2 column are the percent increase between S3,2
and Sf3,2.
Figure 1: Volume measurement error. A. First measured volume y1 against second one y2. Also plotted 
is the regression line (correlation coefficient r = 0.98, slope of the regression = 0.96).  B. Error y1 - ym 
against approximation of the volume given by the average of the two measurement ym = (y1+y2)/2. The χ2 
test rejected Gaussian distribution of constant variance (p = 0.004) C. Histogram of the normalized error 
(y1-ym)/Em applying the error model given by (22) with α = 0.84 and Vm = 83 mm3. It shows Gaussian 
distribution (p = 0.196, χ2 test).
Figure 2: Descriptive power of the models. A. Representative examples of all growth models fitting the same 
growth curve (animal 10 for lung, animal 14 for breast). Errorbars correspond to the standard deviation of the a 
priori estimate of measurement error. In the lung setting, curves of the Gompertz, power law, dynamic CC and von 
Bertalanffy models are visually undistiguinshable. B. Corresponding relative growth rate curves. Curves for von 
Bertalanffy and power law are identical in the lung setting C. Residuals distributions, in ascending order of mean 
RMSE (13) over all animals. Residuals (see formula (15) for their definition) include fits over all the animals and all 
the time points. Exp1 = exponential 1, Exp-L = exponential-linear, Exp = exponential , Log = logistic, GLog = 
generalized logistic, PL = power law, Gomp= Gompertz, VonBert = von Bertalanffy, DynCC = dynamic CC. 
Figure 3: Example of predictive power. Representative example of the forecast performances of the 
models for the lung data set (mouse number 2). Five data points were used to estimate the animal 
parameters and predict future growth. Prediction success of the models are reported for the next day data 
point (OK1) or global future curve (OKglob), based on the criterion of a normalized error smaller than 3 
(meaning that the median model prediction is within 3 standard deviations of the measurement error) for OK1 
and the median of this metric over the future curve for OKglob (see Materials and Methods for details). 
Figure 4: Prediction depth and number of data points. Predictive power of some representative models depending on the 
number of data points used for estimation of the parameters (n) and the prediction depth in the future (d). Top: at position  the 
color represents percentage of successfully predicted animals when using  data points and forecasting the time point tn+d, i.e. 
the score Sn,d (multiplied by 100), defined in (17). This proportion only includes animals having measurements at these two 
time points, thus values at different rows on the same column or reverse might represent predictions in different animals. 
White squares correspond to situations where this number was too low (<5) and thus success score, considered not 
significative, was not reported. Bottom: distribution of the relative error of prediction, all animals and (n,d) settings pooled 
together. Models were ranked in ascending order of overall mean success score reported in Tables 5 and 6. A. Lung tumor 
data. B. Breast tumor data. 
Figure 5: A priori information and 
improvement of prediction success 
rates. Predictions were considered when 
randomly dividing the animals between 
two equal groups, one used for learning 
the parameters distribution and the other 
for prediction, using n=3 data points. 
Success rates are reported as mean ± 
standard deviation over 100 random 
partitions into two groups.Prediction of 
global future curve, quantified by the 
score S3,glob (see Materials and Methods). 
B. Benefit of the method for prediction of 
the next day, using three data points 
(score S3,1). C. Prediction improvement at 
various prediction depths, using the 
power law model (lung data) or the 
exponential-linear model (breast data). 
Due to lack of animals to be predicted for 
some of the random assignments, results 
of depths 2, 4, 6 and 9 for the breast data 
were not considered significant (see 
Materials and Methods). 
*= p < 0.05, ** = p < 0.001, Student’s t-
test
Text S1: Numerical procedures for parameters estimation 
When available, we used the analytical formula of the model for numerical computations. 
This was the case for all the models except the dynamic CC model (5), for which we used 
the ode solver ode45 of Matlab for computation of the solution. 
Several optimization algorithms implemented in Matlab [49] were preliminary tested for 
minimization of �! and the function lsqcurvefit (with trust-region algorithm and maximum 
number of iterations and function evaluations allowed both set to 10!) was decided to be 
well-suited for most of the settings based on its rapidity of convergence and ability to manage 
bounds constraints. Convergence of the algorithm was systematically checked and was 
effective for all the parameter estimations performed (for both the descriptive and predictive 
analysis). Values of the parameters used for initialization of the minimization algorithm were 
fixed from preliminary explorative analysis, sometimes with the help of the more global 
optimizer fminsearch. They are reported in the Table S1 and a short study of the impact of 
the initial guess on the values of the parameters resulting from the optimization is provided in 
the supplementary text S2 and supplementary Table S3.  
We compared the fits obtained by lsqcurvefit to other regression functions implemented in 
Matlab, namely nlinfit (Levenberg-Marquardt algorithm) or fminsearch (Nelder-Mead 
algorithm). For the identifiable models (in the sense of the practical identifiability reported in 
text S2), as well as for the dynamic CC model, no significant differences in the estimated 
parameter sets were observed (Student’s t-test) when comparing fits obtained with either 
nlinfit or fminsearch to the fits of lsqcurvefit. For instance, the relative difference for 
parameters estimates of the full lung data set with the power law model was lower than 
1.5×10
!! and � values of Student’s t-test for significant differences between the population 
distributions of parameter sets were all larger than 0.99. On the other hand, consistently with 
their dependence on the initialization of the optimization algorithm (Table S2), parameters 
estimations of the two non-identifiable models generalized logistic (3) and von Bertalanffy (6), 
were significantly sensitive to the algorithm used. However, for the von Bertalanffy model, 
this difference in the parameters did not impact on the resulting growth curve and generated 
the same fits (identical value of the minimal sum of squared errors). This observation 
suggests a structural non-identifiability of this model for the range of the observed dynamics, 
that is, that different parameter values can generate the same curve. 
Two models required specific attention, namely the generalized logistic model (3) and the 
exponential-linear model (1). In the first setting, due to low identifiability, lsqcurvefit was 
found to converge to irrealistic local minima and we rather used the more global optimizer 
fminsearch with an increased maximum number of iterations and function evaluations 
allowed (from 600 to 105), in order to ensure convergence of the algorithm. Convergence 
was checked a posteriori to be effective. For the exponential-linear model, local minima 
issues were also likely to happen because, on a finite time-course and within some 
parameter ranges, the model could be insensitive to variation of one of the parameter and 
remain in a fully-linear or fully-exponential phase (if the resulting � was larger than the 
maximum time or lower than the minimal one), which could be sub-optimal. A useful 
workaround was to impose upper bounds on the parameters (in particular �!). To avoid 
numerical issues when solving the von Bertalanffy and power law models, we also imposed 
an upper bound on parameter �. In the setting of lsqcurvefit, this required imposition of a 
bound also on parameters � and �, which were taken large enough not to be active. 
Text S2: Practical identifiability of the models 
Sensitivity of the fits obtained from our estimation procedure was assessed for each model 
by systematically varying initialization of the algorithm. Only the LLC tumor data set was 
used for this study, in order to limit the computational cost and because the results should be 
similar with the LM2-4LUC+ data. A compact subset of the parameter space of length 4 
standard deviations was meshed and explored in each parameter direction above and below 
the mean population value from the fits reported in the text (Table 3). For the generalized 
logistic and von Bertalanffy models, due to high inter-animal variability of the parameters 
estimates (Table 3), this method led to extreme values of the parameters. These were not 
relevant initializations because they resulted in extreme, biologically unrealistic, behaviors of 
the models. Starting from these initializations, the minimization procedure was unable to 
generate good fits and consequently the identifiability scores were very low, but for a 
methodological reason and not due to structural properties of the models. Consequently, a 
different procedure was employed. The baseline mean value was taken to be the one of 
Table S1 and standard deviation was replaced by an arbitrary standard deviation of 50% of 
the baseline value. For each model, 20×11! individual fits were performed (for the 20 
animals growth curves) with � the number of parameters in the model, giving a total of 92180 
individual tumor growth performed for the analysis.  
We reported in Table S3 results of sensitivity scores. The first score was defined as the 
fraction of minimization runs (over all the animals and initializations) for which the minimized 
objective (defined in (8)) converged to the same value as when starting from the baseline 
initialization (within a 10% relative error). This score essentially verifies that all the resulting 
fits, even if converging to a different parameter vector than with the baseline initialization, 
were equally good. A low fit score would mean that the optimization algorithm has often 
converged to sub-optimal minima. All of the models had very good fit score (Table S3). 
The second score concerned parametric identifiability and was defined as the fraction of 
minimization runs that converged to the same parameter vector as when performing 
minimization starting from the baseline value (within a 10% relative error). When global 
numerical identifiability was not observed, further investigation on each parameter was 
performed and the resulting variation of the best-fit parameter computed (Table S3). Low 
parametric identifiability scores means that the model was able to generate almost identical 
growth curves with different parameter sets. 
As could be expected from their large standard errors on the parameters estimates (Table 3), 
the models with three parameters (von Bertalanffy (6), dynamic CC (5) and generalized 
logistic (3)) exhibited low parametric identifiability scores (of respectively 34.4%, 45.1% and 
56.5%, out of 26620 fits for each). For the von Bertalanffy model, the non-identifiability was 
probably due to the absence of identifiable range of convergence to an asymptotic volume in 
our data. The low identifiability of the dynamic CC model can be explained by its two-
dimensional nature (volume and carrying capacity are variables) with only one observable 
used for the fits. This fact resulted in variability mostly in estimation of �!. For the 
generalized logistic model, non-identifiability mostly came from parameters � and �. This 
could be explained by the high flexibility of the model that generated several close-to-optimal 
fits, although with different parameter values. Most of the fits (93.6%) were in the range of 
10% from the baseline fit (i.e. the fits used in Table 1). Considering a different 
parameterization of the model (changing � into � =
!
!
) might improve the identifiability of the 
generalized logistic model. 
All the other models exhibited very good robustness in the parameter estimation. 
 
 
 
Table S1: Initializations of the least squares minimization algorithm. 
Model Parameter Initialization Upper bound 
Power law 
� 1 100 
� 2/3 1 
Gompertz 
� 1 - 
� 0.1 - 
Dynamic CC 
� 3 - 
� 0.5 - 
�! 10 - 
Generalized 
logistic 
� 10 - 
� 10000 - 
� 0.01 - 
Von Bertalanffy 
� 1 100 
� 0.75 1 
� 0.1 100 
Exponential �! 
� 0.1 - 
�! 20 - 
Exponential-linear 
�0 0.2 10 
�1 100 200 
Logistic 
� 1 - 
� 10000 - 
Exponential 1 � 0.1 - 
Also reported are bounds used in lsqcurvefit for estimation of parameters of the power law, 
von Bertalanffy and exponential-linear models. 
 
Tables S2: Comparison of individual fits between the individual and popu-
lation approaches. Fits were performed using either an individual estimation of the
growth curves based on weighted least-squares estimation or a population approach. In
both settings, the error model was proportional to the volume to the power α = 0.84.
The only difference was that Monolix estimation did not allow for a setting with a thresh-
old volume Vm, which was thus taken to be 0. However, due to its low value (Vm = 83
mm3), it was not very active in the individual approach. Reported are the mean (over
the time points) weighted least squares (i.e. the ones of the first column of Tables 1, 2
except with Vm = 0, i.e. the Monolix setting), for both approaches. More precisely, if
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with
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φ being the individual estimate of parameter set β in animal j, using either the
individual approach (φ = I) or the population approach (φ = P). The numbers reported
are the mean value of 1
Ij
χ2(
ˆ
β
j
φ) (over the population, i.e. index j) as well as minimal
and maximal values. Note that due to the relatively large volumes of the breast data,
Vm was not active and the values of the individual approach are exactly the ones of
Table 2 in this case (S2.B). Last column is the p-value of Student’s t-test for significant
differences between the individual and population approaches.
S2.A Lung data
Model Indiv. (least squares) Pop. (Monolix) p
DynCC 0.236(0.0143-2.33) 0.515(0.0228-6.66) 0.421
Gomp 0.274(0.0213-2.74) 0.768(0.0422-10) 0.335
PL 0.27(0.0176-2.68) 0.988(0.0362-13.9) 0.308
VonBert 0.256(0.0176-2.74) 0.735(0.032-10.5) 0.374
ExpV0 0.373(0.00718-2.9) 0.947(0.0638-12.4) 0.36
GLog 0.186(0.0213-1.25) 0.799(0.0478-10.3) 0.234
Log 0.349(0.0547-1.81) 0.977(0.12-4.38) 0.0471
Exp-L 0.322(0.0529-1.32) 0.614(0.0621-3) 0.12
Exp1 1.46(0.335-2.58) 2.53(0.924-10.7) 0.0686
S2.B Breast data
Model Indiv. (least squares) Pop. (Monolix) p
DynCC 0.11(0.018-0.503) 0.25(0.0352-1.75) 0.0448
Gomp 0.0976(0.0147-0.328) 0.237(0.039-1.87) 0.0306
PL 0.102(0.0159-0.323) 0.216(0.0311-1.49) 0.0367
VonBert 0.0928(0.0148-0.323) 0.263(0.0337-2.11) 0.0231
ExpV0 0.118(0.0106-0.37) 0.278(0.0121-2.17) 0.0484
GLog 0.0814(0.00366-0.328) 0.226(0.0361-1.8) 0.0181
Log 0.145(0.00367-0.417) 0.178(0.0234-0.66) 0.232
Exp-L 0.0919(0.0159-0.49) 0.113(0.0273-0.615) 0.394
Exp1 2.19(0.617-3.44) 5.88(0.629-27.4) 0.00157
2
Table S3: Practical identifiability. Two identifiability scores were reported.The fit
score is the proportion of minimization runs, among the 20 × NP performed,for which
the resulting minimized objective converged to the same valueas when starting from the
baseline value. The global parametric score is the proportion of minimization runsthat
converged to the same parameter vector, within a 10% relative error.When this last score
was lower than 100%, further analysis was performedand the same score was computed
for each parameter of the model.We also report their median relative deviation to the
base value, in percent.Param. = Parameter. Dev. = Deviation.
Model Fit score
(%)
Global
param.
score (%)
Param. score (%) (Median Dev.)
Power law 100.0 100.0
a γ
100.0 (0.000811) 100.0 (0.000272)
Gompertz 100.0 100.0
a β
100.0 (0.000273) 100.0 (0.000662)
Dynamic CC 85.9 45.1
a b K0
67.3 (0.948) 70.3 (0.491) 45.2 (37.5)
Von Bertalanffy 99.4 34.4
a γ b
77.9 (1.53) 99.3 (0.0181) 34.4 (21.3)
Generalized logistic 93.6 56.5
a K α
56.9 (4.92) 93.4 (0.00149) 57.0 (5.01)
Exponential V0 100.0 100.0
V0 a
100.0 (0.00134) 100.0 (0.000366)
Logistic 97.7 97.7
a K
97.7 (0.001) 97.7 (0.00557)
Exponential-linear 95.0 97.3
a0 a1
97.3 (0.000517) 97.3 (0.00262)
Exponential 1 100.0 100.0
a
100.0 (0.00013)

Figure S2: Examples of individual predictions. Lung data. Prediction success of the
model are reported for the next day (OK1) or global future curve (OKglob), based on the
criterion of a normalized error smaller than 3 (meaning that the median model prediction is
within 3 standard deviations of the measurement error) for OK1 and the median of this metric
over the future curve for OKglob. Future growth was predicted using 5 data points. Plotted here
are results from the Gompertz model.
A. Gompertz model (similar to von Bertalanffy, dynamic CC and power law models)

B. Examples of sharp saturation of the generalized logistic model
Mouse 12 Mouse 14
Mouse 17 Mouse 19
Figure S3: Examples of individual predictions. Breast data. Prediction success of the
model are reported for the second next day data point (OK2) or global future curve (OKglob),
based on the criterion of a normalized error smaller than 3 (meaning that the median model
prediction is within 3 standard deviations of the measurement error) for OK2 and the median of
this metric over the future curve for OKglob. Future growth was predicted using 5 data points
and the exponential-linear model.




